The genetic background of inflammatory bowel disease, both Crohn's disease and
ulcerative colitis, has been known for more than 2 decades. In the last 20 years, genome …

Background: Thiopurines are an important class of immunosuppressants despite their risk
for hematopoietic toxicity and narrow therapeutic indices. Benign neutropenia related to an …

Background Immune-suppressing drugs can cause liver, kidney or blood toxicity. Prognostic
factors for these adverse-events are poorly understood. Purpose To ascertain prognostic …

Azathioprine is commonly used as an immunosuppressive antimetabolite in the treatment of
acute lymphoblastic leukemia, autoimmune disorders (such as Crohn's disease and …

Background Patients established on thiopurines (eg, azathioprine) are recommended to
undergo three-monthly blood tests for the early detection of blood, liver, or kidney toxicity …

Introduction Despite new treatment options for inflammatory bowel disease (IBD),
conventional thiopurines remain a common treatment option for maintaining remission …

The risk of severe adverse events related to thiopurine therapy can be reduced by
personalizing dosing based on TPMT and NUDT15 genetic polymorphisms. However, the …

Inflammatory bowel disease (IBD) represents heterogeneous and relapsing intestinal
conditions with a severe impact on the quality of life of individuals and a continuously …

Background Patients with inflammatory bowel disease (IBD) exhibit considerable
interindividual variability in medication response, highlighting the need for precision …

Genetic variants affect drug responses, making pre‐emptive genotyping crucial for averting
serious adverse events (SAEs) and treatment failure. However, assessing the benefits of pre …